Bill Text: HI SB189 | 2015 | Regular Session | Amended

---

Bill Title: Marijuana; Rescheduling

Spectrum: Partisan Bill (Democrat 5-0)

Status: (Introduced - Dead) 2015-02-26 - The committee on JDL deferred the measure. [SB189 Detail]

Download: Hawaii-2015-SB189-Amended.html

---

THE SENATE	S.B. NO.	189
TWENTY-EIGHTH LEGISLATURE, 2015		S.D. 1
STATE OF HAWAII

A BILL FOR AN ACT

 

 

RELATING TO THE SCHEDULING OF MARIJUANA.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 

     SECTION 1.  The legislature finds that the medical use of marijuana has existed in the State since 2000 when Hawaii became the first state to accept the medical use of marijuana by the legislative process.  However, despite fourteen years of medical use by thousands of patients in the State, marijuana still remains in schedule I, while coca and poppy, plants that contain substances far more dangerous than any substance found in marijuana, are listed in schedule II.

     The purpose of this Act is to reclassify marijuana from as a hallucinogenic substance listed as a schedule I controlled substance to a hallucinogenic substance listed as a schedule II controlled substance.

     SECTION 2.  Section 329-14, Hawaii Revised Statutes, is amended as follows:

     1.  By amending subsection (d) to read:

     "(d)  Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Alpha-ethyltryptamine (AET);

     (2)  2,5-dimethoxy-4-ethylamphetamine (DOET);

     (3)  2,5-dimethoxyamphetamine (2,5-DMA);

     (4)  3,4-methylenedioxy amphetamine;

     (5)  3,4-methylenedioxymethamphetamine (MDMA);

     (6)  N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);

     (7)  3,4-methylenedioxy-N-ethylamphetamine (MDE);

     (8)  5-methoxy-3,4-methylenedioxy-amphetamine;

     (9)  4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);

    (10)  4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

    (11)  3,4,5-trimethoxy amphetamine;

    (12)  Bufotenine;

    (13)  4-methoxyamphetamine (PMA);

    (14)  Diethyltryptamine;

    (15)  Dimethyltryptamine;

    (16)  4-methyl-2,5-dimethoxy-amphetamine;

    (17)  Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4‑hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

    (18)  Ibogaine;

    (19)  Lysergic acid diethylamide;

   [(20)  Marijuana;

    (21)] (20)  Parahexyl;

   [(22)] (21)  Mescaline;

   [(23)] (22)  Peyote;

   [(24)] (23)  N-ethyl-3-piperidyl benzilate;

   [(25)] (24)  N-methyl-3-piperidyl benzilate;

   [(26)] (25)  Psilocybin;

   [(27)] (26)  Psilocyn;

   [(28)] (27)  1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

   [(29)] (28)  Ethylamine analog of phencyclidine (PCE);

   [(30)] (29)  Pyrrolidine analog of phencyclidine (PCPy, PHP);

   [(31)] (30)  Thiophene analog of phencyclidine (TPCP; TCP);

   [(32)] (31)  Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;

   [(33)] (32)  1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4‑dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;

   [(34)] (33)  2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;

   [(35)] (34)  N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;

   [(36)] (35)  1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;

   [(37)] (36)  Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers;

   [(38)] (37)  5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;

   [(39)] (38)  Salvia divinorum;

   [(40)] (39)  Salvinorin A;

   [(41)] (40)  Divinorin A;

   [(42)] (41)  5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names:  5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);

   [(43)] (42)  2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C‑E);

   [(44)] (43)  2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C‑D);

   [(45)] (44)  2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C‑C);

   [(46)] (45)  2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

   [(47)] (46)  2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

   [(48)] (47)  2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

   [(49)] (48)  2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

   [(50)] (49)  2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C‑N);

   [(51)] (50)  2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

   [(52)] (51)  2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

   [(53)] (52)  2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and

   [(54)] (53)  2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

     2.  By amending subsection (g) to read:

     "(g)  Any of the following cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

    [(1)  Tetrahydrocannabinols; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:  Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and Delta 3,4 cis or trans-tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions, are covered);

     (2)] (1)  Naphthoylindoles; meaning any compound containing a 3‑(1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

    [(3)] (2)  Naphthylmethylindoles; meaning any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

    [(4)] (3)  Naphthoylpyrroles; meaning any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;

    [(5)] (4)  Naphthylmethylindenes; meaning any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;

    [(6)] (5)  Phenylacetylindoles; meaning any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent;

    [(7)] (6)  Cyclohexylphenols; meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl ring to any extent;

    [(8)] (7)  Benzoylindoles; meaning any compound containing a 3‑(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

    [(9)] (8)  2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone (another trade name is WIN 55,212-2);

   [(10)] (9)  (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (other trade names are: HU-210 and HU-211);

   [(11)] (10)  Tetramethylcyclopropanoylindoles; meaning any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent;

   [(12)] (11)  N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  APINACA, AKB48);

   [(13)] (12)  Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  PB-22; QUPIC);

   [(14)] (13)  Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  5‑fluoro-PB-22; 5F-PB-22);

   [(15)] (14)  N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  AB-FUBINACA); and

   [(16)] (15)  N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  ADB-PINACA)."

     SECTION 3.  Section 329-16, Hawaii Revised Statutes, is amended by amending subsection (g) to read as follows:

     "(g)  Hallucinogenic substances, unless listed in another schedule, shall include:

     (1)  Nabilone[.]; and

     (2)  Marijuana."

     SECTION 4.  This Act does not affect rights and duties that matured, penalties that were incurred, and proceedings that were begun before its effective date.

     SECTION 5.  Statutory material to be repealed is bracketed and stricken.  New statutory material is underscored.

     SECTION 6.  This Act shall take effect on July 1, 2050.

 

 

Report Title:

Marijuana; Rescheduling

 

Description:

Reclassifies marijuana from a schedule I to a schedule II controlled substance.  Effective 7/1/2050.  (SD1)

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.